Perioperative change in CA125 is an independent prognostic factor for improved clinical outcome in advanced ovarian cancer

M. Timmermans*, N. Zwakman, G. S. Sonke, K. K. Van de Vijver, M. J. Duk, M. A. van der Aa, R. F. Kruitwagen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

7 Citations (Web of Science)

Abstract

Objective: Despite being the most important prognostic factor for prolonged overall survival in epithelial ovarian cancer (EOC), the measurement of residual disease is hampered by its subjective character. Additional assessment tools are needed to establish the success of cytoreductive surgery in order to predict patients' prognosis more accurately. The aim of this study is to evaluate the independent prognostic value of perioperative CA125 change in advanced stage EOC patients.

Study design: We identified all patients who underwent primary cytoreductive surgery for advanced stage (FIGO IIB-IV) EOC between 2008 and 2015, from the Netherlands Cancer Registry. The relative perioperative change in CA125 was categorized into four groups; increase, = 80% decline. Overall survival (OS) was analyzed using Kaplan-Meier survival curves and multivariable cox regression models.

Results: We included 1232 eligible patients with known pre- and postoperative CA125 serum levels. Patients with a decline of >= 80% in CA125 levels experienced improved OS compared to those with a decline of = 80% 0.52(0.41-0.66)).

Conclusions: This study shows that the perioperative change in CA125 is an independent prognostic factor for overall survival after primary surgery for EOC patients. This pleads for the use of a combined model, consisting of perioperative CA125 change and the outcome of residual disease, in order to predict the prognosis of EOC patients more accurately. (C) 2019 Elsevier B.V. All rights reserved.

Original languageEnglish
Pages (from-to)364-369
Number of pages6
JournalEuropean Journal of Obstetrics & Gynecology and Reproductive Biology
Volume240
DOIs
Publication statusPublished - Sep 2019

Keywords

  • Epithelial ovarian cancer
  • CA125
  • Surgery
  • Chemotherapy
  • Overall survival
  • ADVANCED-STAGE OVARIAN
  • GROSS RESIDUAL DISEASE
  • PRIMARY SURGERY
  • SURVIVAL
  • CYTOREDUCTION
  • TUMORIGENESIS
  • CHEMOTHERAPY
  • THERAPY
  • ASCITES
  • DECLINE

Cite this